| Product Code: ETC6187699 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The patented drugs market in Australia is a critical segment of the pharmaceutical industry encompassing prescription medicines under patent protection. This market is driven by ongoing pharmaceutical research and development, strong regulatory support for patent exclusivity, and rising demand for innovative therapies for chronic and rare diseases. Patented drugs often command premium pricing due to their exclusivity and advanced therapeutic benefits. The market faces challenges from patent expirations and the subsequent entry of generic drugs, but remains buoyed by continuous innovation and investment in specialty medicines.
The patented drugs market in Australia continues to be driven by innovation in biologics and specialty pharmaceuticals targeting chronic and rare diseases. The expiry of patents on blockbuster drugs is pushing companies to accelerate pipeline development and adopt lifecycle management strategies. Additionally, government policies encouraging local clinical trials and faster approvals are stimulating market growth.
In the Australia Patented Drugs Market, the primary challenge lies in the high cost and lengthy process of drug development and approval, which can delay market entry. Patent expirations lead to generic competition, significantly impacting revenues. Payers and healthcare providers are increasingly demanding value-based pricing and real-world evidence to justify reimbursement, adding pressure on pharmaceutical companies. Additionally, there is growing regulatory and public scrutiny regarding drug pricing and accessibility, which influences market dynamics.
Australia`s patented drugs market remains attractive due to the government`s Pharmaceutical Benefits Scheme (PBS), which facilitates patient access to advanced therapies. Investors can tap into high-value biologics, oncology drugs, and specialty pharmaceuticals. Strategic alliances with global pharmaceutical firms and investments in local R&D for drug repurposing or biosimilars could yield long-term returns.
The Australian Governments Pharmaceutical Benefits Scheme (PBS) plays a central role in shaping the patented drugs market by subsidizing approved medicines and negotiating prices. Policies under the National Medicines Policy promote equitable access and cost containment, impacting drug companies strategies. Additionally, patent extension rules and data exclusivity regulations, administered by IP Australia, influence innovation incentives and generic competition timelines.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Patented Drugs Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Patented Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Patented Drugs Market - Industry Life Cycle |
3.4 Australia Patented Drugs Market - Porter's Five Forces |
3.5 Australia Patented Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.6 Australia Patented Drugs Market Revenues & Volume Share, By Dosage Form, 2021 & 2031F |
3.7 Australia Patented Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Australia Patented Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic diseases in Australia |
4.2.2 Growing investments in research and development (RD) in the pharmaceutical sector |
4.2.3 Favorable government regulations supporting patent protection for drugs |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval processes for patented drugs |
4.3.2 Competition from generic drug manufacturers |
4.3.3 Pricing pressures and reimbursement challenges in the healthcare system |
5 Australia Patented Drugs Market Trends |
6 Australia Patented Drugs Market, By Types |
6.1 Australia Patented Drugs Market, By Distribution Channel |
6.1.1 Overview and Analysis |
6.1.2 Australia Patented Drugs Market Revenues & Volume, By Distribution Channel, 2021- 2031F |
6.1.3 Australia Patented Drugs Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.1.4 Australia Patented Drugs Market Revenues & Volume, By Drug Store and Retail Pharmacies, 2021- 2031F |
6.1.5 Australia Patented Drugs Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.2 Australia Patented Drugs Market, By Dosage Form |
6.2.1 Overview and Analysis |
6.2.2 Australia Patented Drugs Market Revenues & Volume, By Solid Drug Product, 2021- 2031F |
6.2.3 Australia Patented Drugs Market Revenues & Volume, By Liquid Drug Product, 2021- 2031F |
6.2.4 Australia Patented Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Patented Drugs Market, By Indication |
6.3.1 Overview and Analysis |
6.3.2 Australia Patented Drugs Market Revenues & Volume, By Cardiovascular Diseases, 2021- 2031F |
6.3.3 Australia Patented Drugs Market Revenues & Volume, By Cancer, 2021- 2031F |
6.3.4 Australia Patented Drugs Market Revenues & Volume, By Autoimmune Diseases, 2021- 2031F |
6.3.5 Australia Patented Drugs Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Patented Drugs Market Import-Export Trade Statistics |
7.1 Australia Patented Drugs Market Export to Major Countries |
7.2 Australia Patented Drugs Market Imports from Major Countries |
8 Australia Patented Drugs Market Key Performance Indicators |
8.1 Number of new drug patents granted in Australia |
8.2 Research and development (RD) expenditure in the pharmaceutical industry |
8.3 Percentage of revenue invested in innovation and new product development |
8.4 Time taken for regulatory approval of patented drugs |
8.5 Rate of adoption of patented drugs in the market |
9 Australia Patented Drugs Market - Opportunity Assessment |
9.1 Australia Patented Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.2 Australia Patented Drugs Market Opportunity Assessment, By Dosage Form, 2021 & 2031F |
9.3 Australia Patented Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 Australia Patented Drugs Market - Competitive Landscape |
10.1 Australia Patented Drugs Market Revenue Share, By Companies, 2024 |
10.2 Australia Patented Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here